SCHEMBL198294

SCHEMBL198294

COS(=O)(=O)c1ccccc1Cl

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 3/20 0.46
KDM4E B2RXH2 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
NFE2L2 Q16236 5/20 0.42
PGR P06401 2/20 0.42
KCNH2 Q12809 1/20 0.42
GAA P10253 1/20 0.41
TSHR P16473 1/20 0.41
HSD17B10 Q99714 1/20 0.41
ALDH1A1 P00352 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
HTR6 P50406 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
MCOLN3 Q8TDD5 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29415251 0.84 HTR6 (0.43) KDM4ECYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL777664 0.84 HTR6 (0.43) KDM4ECYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL13290758 0.83 MCOLN3 (0.49) PGRTSHRKMT2AMCOLN3CCR4
SCHEMBL8634554 0.82 HSD11B1 (0.46) HSD11B1KDM4ECYP1A2CYP3A4CYP2D6
SCHEMBL13290726 0.82 HSD11B1 (0.46) HSD11B1NFE2L2KCNH2ALDH1A1HTR6
SCHEMBL15352788 0.80 CCR4 (0.46) MCOLN3CCR4
SCHEMBL16467788 0.80 CYP1A2 (0.48) KDM4ECYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL8144032 0.80 HSD11B1 (0.43) HSD11B1KDM4ECYP1A2CYP3A4CYP2D6
SCHEMBL8712194 0.79 HSD11B1 (0.43) HSD11B1KDM4ECYP1A2CYP3A4CYP2D6
SCHEMBL8854485 0.79 HSD11B1 (0.40) HSD11B1KDM4ECYP1A2CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112759575-B Preparation method of clopidogrel hydrogen sulfate and intermediate N- (2-thienylethyl) methylamine thereof 武汉武药制药有限公司 2022-06-07 CN disclosed
CN-112759575-A Preparation method of clopidogrel hydrogen sulfate and intermediate N- (2-thienylethyl) methylene thereof 武汉武药制药有限公司 2021-05-07 CN disclosed
EP-2841429-B1 TETRAZOLINONE COMPOUNDS AND ITS USE AS PESTICIDES SUMITOMO CHEMICAL CO (JP) 2020-10-21 EP disclosed
US-9565856-B2 Tetrazolinone compounds and its use as pesticides SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-02-14 US disclosed
EP-2841429-A1 TETRAZOLINONE COMPOUNDS AND ITS USE AS PESTICIDES Sumitomo Chemical Company Limited (JP) 2015-03-04 EP disclosed
US-20150051171-A1 TETRAZOLINONE COMPOUNDS AND ITS USE AS PESTICIDES SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2015-02-19 US disclosed
CN-102361837-B Process for producing conjugated aromatic compound SUMITOMO CHEMICAL CO 2014-07-02 CN disclosed
WO-2013162072-A1 TETRAZOLINONE COMPOUNDS AND ITS USE AS PESTICIDES SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2013-10-31 WO disclosed
US-8293905-B2 Bipyridine compound, transition metal complex, and method for production of conjugated aromatic compound using the transition metal complex SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-10-23 US disclosed
CN-102361837-A Process for producing conjugated aromatic compound SUMITOMO CHEMICAL CO 2012-02-22 CN disclosed
US-5922896-A Process for making O,S-dimethyl phosphoramidothioate BAYER CORPORATION (US) 1999-07-13 US disclosed
US-5717124-A Process for preparation of oxyglutaric acid ester derivatives UBE INDUSTRIES, LTD. (JP) 1998-02-10 US disclosed
EP-0239784-B1 CURABLE COMPOSITIONS CONTAINING A POLYEPOXIDE AND A HALOGENATED BISPHENOL THE DOW CHEMICAL COMPANY (US) 1992-05-06 EP disclosed
EP-0205455-B1 CURABLE COMPOSITIONS CONTAINING A POLYEPOXIDE AND A HALOGENATED DIHYDRIC PHENOL AND IMPREGNATED SUBSTRATES AND LAMINATES PREPARED THEREFROM THE DOW CHEMICAL COMPANY (US) 1991-03-13 EP disclosed
US-4783363-A ELECTRICAL LAMINATES THE DOW CHEMICAL COMPANY (US) 1988-11-08 US disclosed
EP-0205455-A4 CURABLE COMPOSITIONS CONTAINING A POLYEPOXIDE AND A HALOGENATED DIHYDRIC PHENOL AND IMPREGNATED SUBSTRATES AND LAMINATES PREPARED THEREFROM. DOW CHEMICAL CO (US) 1988-04-26 EP disclosed
EP-0239784-A2 Curable compositions containing a polyepoxide and a halogenated bisphenol THE DOW CHEMICAL COMPANY (US) 1987-10-07 EP disclosed
EP-0205455-A1 CURABLE COMPOSITIONS CONTAINING A POLYEPOXIDE AND A HALOGENATED DIHYDRIC PHENOL AND IMPREGNATED SUBSTRATES AND LAMINATES PREPARED THEREFROM. DOW CHEMICAL CO (US) 1986-12-30 EP disclosed
US-4604317-A ELECTRICAL LAMINATES THE DOW CHEMICAL COMPANY (US) 1986-08-05 US disclosed
WO-1986002085-A1 CURABLE COMPOSITIONS CONTAINING A POLYEPOXIDE AND A HALOGENATED DIHYDRIC PHENOL AND IMPREGNATED SUBSTRATES AND LAMINATES PREPARED THEREFROM THE DOW CHEMICAL COMPANY (US) 1986-04-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150051171-A1 TETRAZOLINONE COMPOUNDS AND ITS USE AS PESTICIDES CBR3, CYCS, CBR1 HSD11B1 585/4885KDM4E 3020/4885CYP1A2 49/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.